{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T22:39:40Z","timestamp":1768257580249,"version":"3.49.0"},"reference-count":37,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T00:00:00Z","timestamp":1668124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Gilead Sciences Ltd."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Hepatitis C virus (HCV) is prevalent in people with mental health disorders, a priority population to diagnose and cure in order to achieve HCV elimination. This integrated analysis pooled data from 20 cohorts in seven countries to evaluate the real-world effectiveness of the pangenotypic direct-acting antiviral (DAA) sofosbuvir\/velpatasvir (SOF\/VEL) in people with mental health disorders. HCV-infected patients diagnosed with mental health disorders who were treated with SOF\/VEL for 12 weeks without ribavirin as part of routine clinical practice were included. The primary outcome was sustained virological response (SVR) in the effectiveness population (EP), defined as patients with an available SVR assessment. Secondary outcomes were reasons for not achieving SVR, characteristics of patients with non-virological failures, adherence, and time from HCV RNA diagnosis to SOF\/VEL treatment initiation. A total of 1209 patients were included; 142 did not achieve an SVR for non-virological reasons (n = 112; 83 lost to follow-up, 20 early treatment discontinuations) or unknown reasons (n = 30). Of the 1067 patients in the EP, 97.4% achieved SVR. SVR rates in the EP were \u226595% when stratified by type of mental health disorder and other complicating baseline characteristics, including active injection drug use and antipsychotic drug use. Of 461 patients with data available in the EP, only 2% had an adherence level &lt; 90% and 1% had an adherence level &lt; 80%; all achieved SVR. Patients with mental health disorders can be cured of HCV using a well-tolerated, pangenotypic, protease inhibitor-free SOF\/VEL regimen. This DAA allows the implementation of a simple treatment algorithm, with minimal monitoring requirements and fewer interactions with central nervous system drugs compared with protease-inhibitor DAA regimens.<\/jats:p>","DOI":"10.3390\/v14112493","type":"journal-article","created":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T02:34:58Z","timestamp":1668393298000},"page":"2493","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Global Real-World Evidence of Sofosbuvir\/Velpatasvir as a Highly Effective Treatment and Elimination Tool in People with Hepatitis C Infection Experiencing Mental Health Disorders"],"prefix":"10.3390","volume":"14","author":[{"given":"Heiner","family":"Wedemeyer","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, OE6810, Carl-Neuberg-Str. 1, 30625 Hannover, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vito","family":"Di Marco","sequence":"additional","affiliation":[{"name":"University of Palermo, Piazza Marina, 61, 90133 Palermo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6783-7604","authenticated-orcid":false,"given":"Montserrat","family":"Garcia-Retortillo","sequence":"additional","affiliation":[{"name":"Liver Section, Gastroenterology Department, Hospital del Mar-Parc de Salut Mar, Hospital del Mar Medical Research Institute (IMIM), C\/ del Dr. Aiguader, 88, 08003 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"Teti","sequence":"additional","affiliation":[{"name":"Tor Vergata University, Via Cracovia, 50, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Fraser","sequence":"additional","affiliation":[{"name":"Cool Aid Community Health Centre, 713 Johnson St, Victoria, BC V8W 1M8, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0560-3260","authenticated-orcid":false,"given":"Luis Enrique","family":"Morano Amado","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, \u00c1lvaro Cunqueiro University Hospital, Estrada de Clara Campoamor, 341, 36312 Vigo, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3189-7557","authenticated-orcid":false,"given":"Sergio","family":"Rodriguez-Tajes","sequence":"additional","affiliation":[{"name":"Liver Unit, Hospital Clinic Barcelona, IDIBAPS, CIBERehd, C. de Villarroel, 170, 08036 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Acosta-L\u00f3pez","sequence":"additional","affiliation":[{"name":"Digestive Diseases, Hospital Nuestra Se\u00f1ora de Candelaria, Ctra. Gral. del Rosario, 145, 38010 Tenerife, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joss","family":"O\u2019Loan","sequence":"additional","affiliation":[{"name":"Medeco Inala & Kombi Clinic, 55b\/156 Inala Ave, Brisbane, QLD 4077, Australia"},{"name":"School of Medicine, University of Queensland, St Lucia, Brisbane, QLD 4072, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Milella","sequence":"additional","affiliation":[{"name":"Clinic of Infectious Diseases, University of Bari, Piazza Umberto I, 1, 70121 Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Buti","sequence":"additional","affiliation":[{"name":"Liver Unit, Vall d\u2019Hebron University Hospital, and CIBEREHD del Instituto Carlos III, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Fernanda","family":"Guerra-Veloz","sequence":"additional","affiliation":[{"name":"Virgen Macarena University Hospital, Av. Dr. Fedriani, 3, 41003 Seville, Spain"},{"name":"Clinical Research Fellow in Hepatology at King\u2019s College Hospital, Denmark Hill, London SE5 9RS, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alnoor","family":"Ramji","sequence":"additional","affiliation":[{"name":"University of British Columbia, Vancouver, BC V6T 1Z4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Fenech","sequence":"additional","affiliation":[{"name":"Queensland Injectors Health Network (QuIHN), Treatment and Management Programme, 1 Hamilton Pl, Bowen Hills, Brisbane, QLD 4006, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Martins","sequence":"additional","affiliation":[{"name":"Hospital Prof. Dr. Fernando Fonseca, IC19, 2720-276 Amadora, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio M.","family":"Borgia","sequence":"additional","affiliation":[{"name":"Infectious Diseases, William Osler Health System, 2100 Bovaird Dr E, Brampton, ON L6R 3J7, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim","family":"Vanstraelen","sequence":"additional","affiliation":[{"name":"Gilead Sciences Europe Ltd., Stockley Park, 2 Roundwood Ave, Hayes, Uxbridge UB11 1AS, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Mertens","sequence":"additional","affiliation":[{"name":"Gilead Sciences Europe Ltd., Stockley Park, 2 Roundwood Ave, Hayes, Uxbridge UB11 1AS, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e1ndido","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Gilead Sciences Europe Ltd., Stockley Park, 2 Roundwood Ave, Hayes, Uxbridge UB11 1AS, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioanna","family":"Ntalla","sequence":"additional","affiliation":[{"name":"Gilead Sciences Europe Ltd., Stockley Park, 2 Roundwood Ave, Hayes, Uxbridge UB11 1AS, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heribert","family":"Ramroth","sequence":"additional","affiliation":[{"name":"Gilead Sciences Europe Ltd., Stockley Park, 2 Roundwood Ave, Hayes, Uxbridge UB11 1AS, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6035-9953","authenticated-orcid":false,"given":"Scott","family":"Milligan","sequence":"additional","affiliation":[{"name":"Trio Health Analytics, 1025 Cannon Street, Suite 2C, Louisville, CO 80027, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,11]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2022, November 09). Global Health Sector Strategy on Viral Hepatitis 2016\u20132021. Towards Ending Viral Hepatitis. Available online: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/246177\/WHO-HIV-2016.06-eng.pdf?sequence=1."},{"key":"ref_2","unstructured":"World Health Organization (2022, November 09). Interim Guidance for Country Validation of Viral Hepatitis Elimination. Available online: https:\/\/www.who.int\/publications\/i\/item\/9789240028395."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jhep.2020.07.042","article-title":"Impact of COVID-19 on global HCV elimination efforts","volume":"74","author":"Blach","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","article-title":"EASL recommendations on treatment of hepatitis C: Final update of the series","volume":"73","author":"Pawlotsky","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.jhep.2012.07.037","article-title":"Hepatitis C infection, antiviral treatment and mental health: A European expert consensus statement","volume":"57","author":"Schaefer","year":"2012","journal-title":"J. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/SGA.0000000000000459","article-title":"Characteristics of adults with hepatitis C virus: Evidence from the National Health and Nutrition Examination Survey 2011\u20132012","volume":"43","author":"Williams","year":"2020","journal-title":"Gastroenterol. Nurs."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S2215-0366(15)00357-0","article-title":"Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness: A systematic review and meta-analysis","volume":"3","author":"Hughes","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S2215-0366(17)30253-5","article-title":"Prevalence and risk factors for HIV, hepatitis B, and hepatitis C in people with severe mental illness: A total population study of Sweden","volume":"4","author":"Lewis","year":"2017","journal-title":"Lancet Psychiatry"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.genhosppsych.2019.10.007","article-title":"Rates of hepatitis B and C in patients with schizophrenia: A meta-analysis","volume":"61","author":"Lluch","year":"2019","journal-title":"Gen. Hosp. Psychiatry"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1007\/s12072-021-10195-6","article-title":"Liver disease prevalence and severity in people with serious mental illness: A cross-sectional analysis using non-invasive diagnostic tools","volume":"15","author":"Braude","year":"2021","journal-title":"Hepatol. Int."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Sundberg, I., Lannerg\u00e5rd, A., Ramklint, M., and Cunningham, J.L. (2018). Direct-acting antiviral treatment in real world patients with hepatitis C not associated with psychiatric side effects: A prospective observational study. BMC Psychiatry., 18.","DOI":"10.1186\/s12888-018-1735-6"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/hep.31060","article-title":"AASLD-IDSA Hepatitis C Guidance Panel. Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection","volume":"71","author":"Ghany","year":"2020","journal-title":"Hepatology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"116","DOI":"10.9740\/mhc.2018.05.116","article-title":"Evaluating psychiatric outcomes associated with direct-acting antiviral treatment in veterans with hepatitis C infection","volume":"8","author":"Sackey","year":"2018","journal-title":"Ment. Health Clin."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Gallach, M., Vergara, M., da Costa, J.P., Miquel, M., Casas, M., Sanchez-Delgado, J., Dalmau, B., Rudi, N., Parra, I., and Monllor, T. (2018). Impact of treatment with direct-acting antivirals on anxiety and depression in chronic hepatitis C. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0208112"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/hep.30171","article-title":"Has access to hepatitis C virus therapy changed for patients with mental health or substance use disorders in the direct-acting-antiviral period?","volume":"69","author":"Jain","year":"2019","journal-title":"Hepatology"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Davidson, K., Boyle, A., Barclay, S., Boxall, E., Fleming, C., Gossman, P., McAvennie, J., Reilly, E., Sheridan, E., and Sommerville, A. (2020, January 27\u201329). The quetiapine question: Management strategies for drug-drug interactions with antipsychotics and direct acting antivirals; a multicentre review. Proceedings of the Digital International Liver Congress, Poster #THU424.","DOI":"10.1016\/S0168-8278(20)31196-X"},{"key":"ref_17","first-page":"279","article-title":"Concomitant use of direct-acting antivirals (DAA) and central nervous system drugs in patients with hepatitis C virus infection","volume":"34","year":"2020","journal-title":"Adicciones"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1007\/s40262-016-0407-2","article-title":"Drug-drug interactions between direct-acting antivirals and psychoactive medications","volume":"55","author":"Smolders","year":"2016","journal-title":"Clin. Pharmacokinet."},{"key":"ref_19","unstructured":"(2022, November 09). Liverpool HEP Interactions. Available online: https:\/\/www.hep-druginteractions.org\/checker."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection","volume":"373","author":"Feld","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","article-title":"Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection","volume":"373","author":"Foster","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","article-title":"Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis","volume":"373","author":"Curry","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/cid\/cix260","article-title":"Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study","volume":"65","author":"Wyles","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1111\/liv.14537","article-title":"Global real-world evidence of sofosbuvir\/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts","volume":"40","author":"Mangia","year":"2020","journal-title":"Liver Int."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s40121-021-00576-7","article-title":"Sofosbuvir\/Velpatasvir for Hepatitis C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in Taiwan","volume":"11","author":"Cheng","year":"2021","journal-title":"Infect. Dis. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2217\/fvl-2021-0266","article-title":"Real-world evidence of sofosbuvir\/velpatasvir as an effective and simple hepatitis C virus treatment and elimination tool in homeless populations","volume":"17","author":"Conway","year":"2022","journal-title":"Future Virol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2217\/fvl-2022-0016","article-title":"Real-world effectiveness of sofosbuvir\/velpatasvir for the treatment of hepatitis C virus in prison settings","volume":"17","author":"Rosati","year":"2022","journal-title":"Future Virol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.japh.2020.08.028","article-title":"HCV eradication in veterans with underlying mental health disorders and substance use","volume":"60","author":"Ifeachor","year":"2020","journal-title":"J. Am. Pharm. Assoc."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/jvh.13228","article-title":"Loss to follow-up: A significant barrier in the treatment cascade with direct-acting therapies","volume":"27","author":"Darvishian","year":"2020","journal-title":"J. Viral Hepat."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/add.14128","article-title":"Direct-acting antiviral treatment of chronic HCV-infected patients on opioid substitution therapy: Still a concern in clinical practice?","volume":"113","author":"Christensen","year":"2018","journal-title":"Addiction"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1178221819835847","DOI":"10.1177\/1178221819835847","article-title":"Alcohol and Cannabis Consumption Does Not Diminish Cure Rates in a Real-World Cohort of Chronic Hepatitis C Virus Infected Patients on Opioid Substitution Therapy\u2014Data From the German Hepatitis C-Registry (DHC-R)","volume":"13","author":"Christensen","year":"2019","journal-title":"Subst. Abus. Res. Treat."},{"key":"ref_32","unstructured":"Sulkowski, M., Feld, J., Reau, N., Scherbakovsky, S., Hern\u00e1ndez, C., Vanstraelen, K., Hammond, K., Kreter, B., Suri, V., and Ni, L. (2021, January 23\u201326). Concordance between SVR4, SVR12, and SVR24 in HCV-infected patients who received fixed-dose combination sofosbuvir\/velpatasvir in Phase 3 clinical trials. Proceedings of the International Liver Congress, Virtual Event. Poster #983."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1111\/jvh.13600","article-title":"Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir\/pibrentasvir in Phase 2 and 3 clinical trials","volume":"28","author":"Gane","year":"2021","journal-title":"J. Viral. Hepat."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Mangia, A., Scaglione, F., Toniutto, P., Pirisi, M., Coppola, N., Di Perri, G., Nieto, G.A., Calabrese, S., Hernandez, C., and Perrone, V. (2021). Drug\u2013Drug Interactions in Italian Patients with Chronic Hepatitis C Treated with Pangenotypic Direct Acting Agents: Insights from a Real-World Study. Int. J. Environ. Res. Public Health, 18.","DOI":"10.3390\/ijerph18137144"},{"key":"ref_35","unstructured":"Fagiouli, S., Milligan, S., Turn\u00e9s, J., Mangia, A., Hintz, A., Wick, N., Sicras, A., Esposti, LD., Tacke, F., and Morillo, R. (2021, January 18\u201320). Multinational evaluation of comedication and drug\u2013drug interactions in hepatitis C patients treated with pangenotypic direct-acting antivirals. Proceedings of the Global Hepatitis Summit, Taipei, Taiwan."},{"key":"ref_36","unstructured":"AASLD\/EASL\/APASL\/ALEH (2022, November 09). Call to Action for Liver Associations to Advance Progress Towards Viral Hepatitis Elimination: A Focus on Simplified Approaches to HCV Testing and Cure. Available online: https:\/\/www.aasld.org\/call-action-advance-progress-towards-viral-hepatitis-elimination."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S2468-1253(21)00397-6","article-title":"A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): A phase 4, open-label, single-arm trial","volume":"7","author":"Solomon","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/14\/11\/2493\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:14:23Z","timestamp":1760145263000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/14\/11\/2493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,11]]},"references-count":37,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["v14112493"],"URL":"https:\/\/doi.org\/10.3390\/v14112493","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,11]]}}}